Florence Allouche

PharmD – Paris University, MBA – HEC Paris , Board director certified – IFA/Sciences Po Paris. Biologist at AP-HP (Greater Paris Hospitals). She has several positions in diagnostics industry.

She created and ran for 16 years, the Tech Transfer Office of AP-HP. 1000 patent families filed, 300 license agreements signed, €25M of annual revenues, 75 startups created. Expert & mentor at the main Paris’s incubators, she represented French technology transfer at international level (AUTM, ASTP).

In 2016, Florence Allouche co-founded and was CEO of SPARINGVISION, a genomic medicines company. Translating 20 years of world-leading ophthalmic research at the Paris’ Vision Institute, into vision saving treatments for retinitis pigmentosa, moving beyond single gene correction therapies to gene-independent treatments. SparingVision raised €60M and got several grants.

Florence is Professor at University Paris Cité, Faculty of Pharmacy, specialized in pharmaceutical innovation and entrepreneurship. Florence is founder and President of MYRPHARM ADVISORS, a consulting firm helping translational academic research by startup creation, tech transfer, business development, innovation management, funding, strategy, growth, and mentoring.

(Member of the French National Academy of Pharmacy, Member of the Scientific Advisory Board of Venture Center of Excellence – EIT Health, Prev. Member of the Watching Committee for the Big Investment Plan under the authority of French Prime Minister (SGI), First Prize Biotech at the European Startups Competition CATAPULT 2019, Finalist of the Prix Galien International, New York (US) – Med’Startup, 2019, Mercure Entrepreneurs Award – HEC Paris 2019, Women Trajectory’s Award – HEC Paris 2018, Elected “Woman of the Year 2017” by the French financial magazine “La Tribune”)